Molecular versus conventional markers in pancreatic cancer

Digestion

Volumn 58, Issue 6, 1997, Pages 557-563

  Friess, H ^a   Kleeff, J ^a   Gumbs, A ^a   Buchler M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Gene mutations; Growth factor receptors; Growth factors; Pancreatic cancer; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PROTEIN P53; TUMOR ANTIGEN; TUMOR MARKER;

BILE; BLOOD; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; EARLY CANCER; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FOLLOW UP; GENE MUTATION; HUMAN; MOLECULAR GENETICS; ONCOGENE K RAS; PANCREAS CANCER; PATIENT MONITORING; PRIORITY JOURNAL;

GENETIC MARKERS; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030724514     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201501     Document Type: Article

References (81)

1. National Cancer Institute: Annual Cancer Statistics Review 1973-1988, Bethesda, Department of Health and Human Services, 1991, NIH publication No 91-2789.
2. Parker SL, Tong T, Bolden S, Wingo PA, Cancer statistics, 1997, CA 1997;47:5-27.
3. Warshaw AL, Fcmandez-Del Castillo C: Pancreatic carcinoma, N Engl J Med 1992:326: 455-465.
4. Lee YT, Williams M: Clinical and laboratory findings of carcinoma of the pancreas and periampullary' structures, J Surg Oncol 1994: 25:1-7.
5. Koprowski H, Steplewski Z, Mitchell K, et al: Colorectal carcinoma antigens delected by hy-bridoma antibodies, Somat Cell Genet 1979:5: 957-972.
6. Safi F, Beger HG, Bittner R, Buchlcr MW, et al: Ca 19-9 and pancreatic adenocarcinoma, Cancer 1985;57:779-783.
7. Steinberg WM, Gelfand R, Anderson K.K, et al: Comparison of the sensitivity and specificity of the Ca 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas, Gastroenterology 1986:90:343-349.
8. Safi F, Schlosser W, Falkenreck S, Beger HG: Ca 19-9 serum course and prognosis of pancreatic cancer, Int J Pancrcatol 1996:20:155-161.
9. Forsmark CE, Lambiase L, Vogel SB: Diagnosis of pancreatic cancer adn prediction of unresectability using the tumor associated antigen Ca 19-9, Pancreas 1994;9:703-706.
10. Serti C, Pasquali C, Catalini S, et al: Ca 19-9 as a prognostic index after resection for pancreatic cancer, J Surg Oncol 1993;52:137-141.
11. Satake K, Takcuchi T, Homma T, et al: Ca 19-9 as a screening and diagnostic tool in symptomatic patients: The Japanese experience, Pancreas 1994;9:703-706.
12. Frchourg T, BercofT E, Manchon N, et al: The evaluation of Ca 19-9 antigen level in the early detection of pancreatic cancer, Cancer 1988: 62:2287-2290.
13. Malcsci A, Tontmasini MA, Bonalo, C et al: Determination ofCa 19-9antigen in serum and pancreatic juice for differential diagnosis of pancreatic carcinoma from chronic pancreatitis, Gastroenterology 1987:92:60-67.
14. Haglund C, Lundin J, Kuusela P, et al: Ca 242, a new tumor marker for pancreatic cancers: A comparison with Ca 19-9, Ca 50andCEA, Br J Cancer 1994:70:487-492.
15. Palson B, Masson P, Andren-Sandberg A: Tumour marker Ca 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer, Eur J Surg Oncol 1997;23:151-156.
16. Bosslct K, Kern HE, Kanzy FJ, et al: A monoclonal antibody with binding and inhibitory activity on human pancreatic carcinoma cells, Cancer Immunol Immunther 1986:23:185-191.
17. Buchler M, Friess H, Schultheiss KH, et al: A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/ 32) in resectable pancreatic cancer, Cancer 1991;68:1507-1512.
18. Friess H, Buchlcr M, Auerbach B, et al: Ca494: A new tumor marker for the diagnosis of pancreatic cancer, Int J Cancer 1993:53:759-763.
19. Nilson O, Jansson EL, Johansson C, et al: Ca 242, a novel tumor-associated carbohydrate antigen with increased tumor specificity and sensitivity, J Tumor Marker Oncol 1988:3: 314-319.
20. Rothlin MA, Joller H, Largadier F: Ca 242 is a new tumor marker for pancreatic cancer, Cancer 1992;71:701-707.
21. Gansauge F, Gansauge S, Parker N, et al: CAM 17.1-a new diagnostic marker in pancreatic cancer, BrJ Cancer 1996;74:1997-2002.
22. Yiannakou J Y, Ncwland I, Calder F, et al: Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer, Lancet 1997:349:389-392.
23. Podolsky DK, McPhee MS, Alpert E, et al: Gal-actosyltransfcrasc isoenzyme IHn the detection of pancreatic cancer, Comparison with radiologic, endoscopic, and serologic tests, N Engl J Med 1981;304:1313-1318.
24. Haitiano H, Hayakawa T, Kondo T: Serum immunorcactivc elastase in diagnosis of pancreatic disease: a sensitive marker for pancreatic cancer, DigDisSci 1987:32:50-56.
25. Robles-Diaz G, Diaz-Sanchcz V, Mendez JP, et al: Low serum teslostcrone/dihydrotestosle-ronc ration in patients with pancreatic carcinoma, Pancreas 1987;2:684-687.
26. Kalthoff H, Schmiegel W, Roeder C, et al: p53 and K-ras alterations in pancreatic epithelial lesions, Oncogene 1993:8:289-298.
27. Casey G, Yamanaka Y, Friess H, et al: p53 mutations are common in pancreatic cancer and absent in chronic pancreatitis, Cancer Lett 1993;69:151-160.
28. Levine AJ, Montand J, Finlay CA: The p53 tumor suppressor gene, Nature 1991:351:453-456.
29. Almoguera C, Shibata D, Forrester K, et al: Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes, Cell 1988: 53:549-554.
30. Friess H, Kleeff J, Berberal P, Büchler MW: Clinical applicability of molecular procedures in the diagnosis of pancreatic cancer; in Malfer-theiner P, Dominguez-Muñoz JE, Schulz HU, Lippcrt H (eds): Diagnostic Procedures in Pancreatic Disease, Berlin, Springer, 1997, pp 411-423.
31. Hollcnslein M, Sidranskv D, Vogelslein B, et al: p53 mutations in human cancers, Science 1991;253:49-53.
32. Levine AJ: The 1993 Walter Hubert Lecture: The role of the p53 tumour suppressor gene in tumorigenesis, Br J Cancer 1994:69:409-416.
33. Levine AJ: The p53 tumour suppressor gene and product, Cancer Surv 1992:12:59-79.
34. Vogelstein B, Kinzler KW: The multistcp nature of cancer, Trends Genet 1993:9:138-141.
35. Crawford LV, Pirn DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer, Int J Cancer 1992;30:403-408.
36. Schlichtholz B, Tredanic! J, Lubin R, et al: Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein, Br J Cancer 1994; 69:809-816.
37. Barton CM, Sladdo SL, Hughes CM, et al: Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer, Br J Cancer 1991:64:1076-1082.
38. Dillcr L, Kassel J, Nelsonn CE, et al: p53 functions as a cell cycle control protein in osteosarcoma, Mol Cell Biol 1990;10:5772-5781.
39. Yokoyama Y, Yamanaka Y, Friess H, et al: p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness, Anticanccr Res 1994;14:2477-2484.
40. Laurent-Puig P, Lubin R, Scmhoun-Ducloux S, et al: Antibodies against p53 protein in the serum of patients wit benign or malignant and biliary diseases, Gut 1995;36:455-458.
41. Grünewald K, Lyons J, Frohlich A, et al: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinoma, Int J Cancer 1989,43: 1037-1041.
42. Lemoine NR, Jain S, Hughes CM, et al: Kiras oncogene activation in preinvasivc pancreatic cancer, Gastroenterology 1992:230-236.
43. Pcllegata NS, Sessa F, Renault B, et al: K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions, Cancer Res 1994:54: 1556-1560.
44. Van Laethem J-L, Vertongen P, Deviere J, et al: Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumors, Gut 1995:36: 781-787.
45. Caldas C, Hahn SA, Hurban RH, et al: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia, Cancer Res 1994:54: 3568-3573.
46. Abbruzzcse JL, Evans DB, Raijman I, Larry L, King T, Leach SD, Frazier ML: Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer, Anticancer Res 1997; 17: 795-801.
47. Aaronson SA: Growth factors and cancer, Science 1991;254:1146-1153.
48. Kingsley DM: The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms, Genes Dev 1994;8:133-146.
49. Coussens L, Yank-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science 1985,230: 1132-1139.
50. Kraus MH, Issing W, Miki T, Popescu NC, et al: Isolation and characterization of ERBB3, a third member of the ERBB/cpidcrmal growth factor receptor family: Evidence for ovcrex-pression in a subset of human mammary tumors, Proc Natl Acad Sci USA 1989:86:9193-9197.
51. Plowman GD, Culouscou MJ, Whitney GS, et al: Ligand specific activation of HER4/p l80crbB4, a fourth member of the epidermal growth factor receptor family, Proc Natl Acad Sci USA 1993:90:1746-1750.
52. Schlessingcr J, Ulrich A: Growth factor signaling by receptor tyrosine kinases, Neuron 1992; 9:383-391.
53. Pawson T, Schlessingcr J: SH2 and SH3 domains, Curr Biol 1993;3:434-442.
54. Cadcna DL, Gill GN: Receptor tyrosine kinases, FASEBJ 1992;6:2332-2337.
55. Aim AG: The MAP kinase cascade, Discovery of a new signal transduction pathway, Mol Cell Biochcm 1993:127:201-209.
56. Massague J, Pandiella A: Membrane-anchored growth factors, Annu Rev Biochem 1993:62: 515-541.
57. Kore M, Chandrasekar B, Yamanaka Y, Friess H, et al: Overcxpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha, J Clin Invest 1992:90:1352-1360.
58. Yamanaka Y, Friess H, Kobrin MS, et al: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness, Anticanccr Res 1993:13:565-570.
59. Hall PA, Hughes CM, Staddon SL, et al: The c-erbB-2 prontooncogcne in human pancreatic cancer, J Pathol 1990; 161:1995-2000.
60. Holmes WE, Sliwkowski MX, Aakita RW: Identification of heregulin, a specific activator of p 185crbB2, Science 1992:256:1205-1210.
61. Marchionni MA, Goodearl ADJ, Chen MS: Glial growth factors arc alternatively spliced erbB2 ligands expressed in the nervous system, Nature 1993;362:312-318.
62. Yamanaka Y, Friess H, Kobrin MS, et al: Over-expression of HER2/ncu oncogene in human pancreatic cancer, Hum Pathol 1993:24:1127-1134.
63. Friess H, Yamanaka Y, Kobrin MS, et al: Enhanced erb-B3 expression in human pancreatic cancer correlates with tumor progression, Clin Cancer Res 1995:1:1413-1420.
64. Schlessingcr J, Ulrich A: Growth factor signaling by receptor tyrosine kinases, Neuron 1992; 9:383-391.
65. Yokoyama M, Funatomi H, Kobrin MS, et al: Betacellulin, a member of the epidermal growth factor family is ovcrcxpressed in human pancreatic cancer, Int J Oncol 1995:7: 825-829.
66. Yokoyama M, Funatomi H, Hope C, et al: Heparin-binding EGF-like growth factor expression and biological action in human pancreatic cancer cells, Int J Oncol 1996:8:289-295.
67. Ebert M, Yokoyama M, Friess H, et al: Induction and expression of amphiregulin in human pancreatic cancer, Cancer Res 1994:54:3959-3962.
68. Yokoyama M, Ebert M, Funatomi H, et al: Amphiregulin is a potent mitogen in human pancreatic cancer cells: Correlation with patient survival, Int J Oncol 1995:6:625-631.
69. Folkman J, Klagsbrun M: Angiogenic factors, Science 1987:235:442-447.
70. Gospodcrowicz D, Ncufcld G, Schweigcrer L: Molecular and biological characterization of fibroblast growth factor, an angiogenic factor which also controls the proliferation and differentiation of mesoderm and neuroectodcrm derived cells, Cell Differ 1986:19:1-17.
71. Gospodcrowicz D, Fcrrera N, Sctnveigercr L, et al: Structural characterization and biological functions of fibroblast growth factor, Endocr Rev 1987:8:95-114.
72. Klagsbrun M: The fibroblast growth factor family: Structural and biological properties, Prog Growth Factor Res 1989;1:207-235.
73. Kobrin MS, Yamanaka Y, Friess H, et al: Aberrant expression of the type I fibroblast growth factor receptor in human pancreatic adenocarcinoma, Cancer Res 1993:53:4741-4744.
74. Yamanaka Y, Friess H, Biichlcr MW, et al: Overcxpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage, Cancer Res 1993:53:5289-5296.
75. Finch PW, Rubin JS, Miki T, Ron D, Aaronson SA: Human KGF is FGF-rclated with properties of a paracrine effector of epithelial cell growth, Science 1989:245:752-755.
76. Sidiqi I, Funatomi H, Kobrin MS, Friess H, et al: Increased expression of kcratinozytc growth factor in human pancreatic cancer, Biochem Biophys ResCommun 1995;215:309-315.
77. Friess H, Yamanaka Y, Buchler MW, et al: Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor, Cancer Res 1993:53:2704-2707.
78. Lin HY, Wang X-F, Ng-Eaton E, et al: Expression cloning of the TGF-beta type 11 receptor, a functional transmembrane serine/threonine kinase, Cell 1992;68:775-785.
79. Wrana JL, Attisano L, Carcamo J, et al: TGF-beta signals through a hcteromcric protein kinase receptor complex, Cell 1992:71:1003-1014.
80. Lin HY, Lodish HF: Receptors for the TGF-beta superfamily: Multiple polypeptides and serine/thcronine kinases, Trends Cell Biol 1992:3:14-19.
81. Friess H, Yamanaka Y, Büchler MW, et al: Enhanced expression of transforming growth factor beta isoformes in pancreatic cancer correlates with decreased survival, Gastroenterology 1993:105:1846-1856.